Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
Show with Joel Block, “Your Advantage Play®, In Search of the Ultimate Competitive Advantage”
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing. Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work. In this week’s episode, Mr. Nathanielsz discusses the competitive advantage of the Company and its enzyme treatment for metastatic cancer. Some key points to the competitive advantage highlighted by Mr. Nathanielsz include:
Global Financing Strategy: Mr. Nathanielsz emphasizes the company's global view on accessing funds and its current pursuit of series A financing, showcasing a strategic approach to securing financial support. Role of Being Public: Going public in the U.S. enabled the company to raise significant capital, highlighting the advantages of being a small public company in accessing funding and fostering advancements in drug development. Ethical Communication and Due Diligence: Mr. Nathanielsz underscores the importance of ethical communication and thorough due diligence to build credibility, emphasizing the company's commitment to honesty and integrity in drug development. Drug Development Milestones and Patient Access: The company's main objective is to make their drug accessible to as many patients as possible, prioritizing patient impact over company success, reflecting a patient-centric approach to healthcare. Science-Based Differentiation and Market Opportunity: The guest emphasizes prior human experience with the drug, safety, and efficacy, and its differentiation in the oncology market, identifying a strong scientific foundation for competitive advantage. The show, entitled, “Your Advantage Play®, In Search of the Ultimate Competitive Advantage,” has been on the air for 5 years with over 185 episodes released. It has been rated in the top 5% of all podcasts worldwide and featured CEOs of several public companies as well as some of the most highly regarded advisory talent in the country. It targets senior executives of middle market companies (generally $20 million to $1 billion in annual revenues) – but also includes a wider audience of C-Suite executives from all segments of corporate America.
Mr. Block is a blackjack player turned venture capitalist and hedge fund manager who has participated in $1 billion dollars' worth of deals. Joel Block has adapted these skills, attitudes, and philosophies to business. His keynote speeches and media appearances expose Advantage Play® (AP), the art of knowing what comes next because, for APs, winning is inevitable.
